Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Immunosuppressive properties of a series of novel inhibitors of the monocarboxylate transporter MCT-1.

Påhlman C, Qi Z, Murray CM, Ferguson D, Bundick RV, Donald DK, Ekberg H.

Transpl Int. 2013 Jan;26(1):22-9. doi: 10.1111/j.1432-2277.2012.01579.x. Epub 2012 Nov 8.

2.

The specific monocarboxylate transporter-1 (MCT-1) inhibitor, AR-C117977, induces donor-specific suppression, reducing acute and chronic allograft rejection in the rat.

Ekberg H, Qi Z, Pahlman C, Veress B, Bundick RV, Craggs RI, Holness E, Edwards S, Murray CM, Ferguson D, Kerry PJ, Wilson E, Donald DK.

Transplantation. 2007 Nov 15;84(9):1191-9.

PMID:
17998876
3.

Operational tolerance in nonvascularized transplant models induced by AR-C117977, a monocarboxylate transporter inhibitor.

Påhlman C, Malm H, Qi Z, Veress B, Ferguson D, Bundick R, Murray C, Donald D, Ekberg H.

Transplantation. 2008 Oct 27;86(8):1135-8. doi: 10.1097/TP.0b013e318186b978.

PMID:
18946353
4.

The specific monocarboxylate transporter (MCT1) inhibitor, AR-C117977, a novel immunosuppressant, prolongs allograft survival in the mouse.

Bueno V, Binet I, Steger U, Bundick R, Ferguson D, Murray C, Donald D, Wood K.

Transplantation. 2007 Nov 15;84(9):1204-7.

PMID:
17998878
5.

Mechanism analysis of long-term graft survival by monocarboxylate transporter-1 inhibition.

Cho KS, Yamada T, Wynn C, Behanna HA, Hong IC, Manaves V, Nakanishi T, Hirose J, Abe Y, Jiang H, Tamura K, Saita Y.

Transplantation. 2010 Dec 27;90(12):1299-306. doi: 10.1097/TP.0b013e3181ff8818.

PMID:
21076380
6.

Monocarboxylate transporter MCT1 is a target for immunosuppression.

Murray CM, Hutchinson R, Bantick JR, Belfield GP, Benjamin AD, Brazma D, Bundick RV, Cook ID, Craggs RI, Edwards S, Evans LR, Harrison R, Holness E, Jackson AP, Jackson CG, Kingston LP, Perry MW, Ross AR, Rugman PA, Sidhu SS, Sullivan M, Taylor-Fishwick DA, Walker PC, Whitehead YM, Wilkinson DJ, Wright A, Donald DK.

Nat Chem Biol. 2005 Dec;1(7):371-6.

PMID:
16370372
7.

Potent blockers of the monocarboxylate transporter MCT1: novel immunomodulatory compounds.

Guile SD, Bantick JR, Cheshire DR, Cooper ME, Davis AM, Donald DK, Evans R, Eyssade C, Ferguson DD, Hill S, Hutchinson R, Ingall AH, Kingston LP, Martin I, Martin BP, Mohammed RT, Murray C, Perry MW, Reynolds RH, Thorne PV, Wilkinson DJ, Withnall J.

Bioorg Med Chem Lett. 2006 Apr 15;16(8):2260-5. Epub 2006 Feb 7.

PMID:
16455256
8.

Characterization of monocarboxylate transport in human kidney HK-2 cells.

Wang Q, Lu Y, Yuan M, Darling IM, Repasky EA, Morris ME.

Mol Pharm. 2006 Nov-Dec;3(6):675-85.

PMID:
17140255
9.

The inhibition of monocarboxylate transporter 2 (MCT2) by AR-C155858 is modulated by the associated ancillary protein.

Ovens MJ, Manoharan C, Wilson MC, Murray CM, Halestrap AP.

Biochem J. 2010 Oct 15;431(2):217-25. doi: 10.1042/BJ20100890.

10.

The effect of a new immunosuppressive drug, brequinar sodium, on heart, liver, and kidney allograft rejection in the rat.

Cramer DV, Chapman FA, Jaffee BD, Jones EA, Knoop M, Hreha-Eiras G, Makowka L.

Transplantation. 1992 Feb;53(2):303-8.

PMID:
1531394
11.

Intracellular lactate flux: a new regulator of the allogenic immune response.

Durrbach A, Francois H.

Transpl Int. 2013 Jan;26(1):20-1. doi: 10.1111/tri.12035. No abstract available.

12.

AR-C155858 is a potent inhibitor of monocarboxylate transporters MCT1 and MCT2 that binds to an intracellular site involving transmembrane helices 7-10.

Ovens MJ, Davies AJ, Wilson MC, Murray CM, Halestrap AP.

Biochem J. 2010 Jan 15;425(3):523-30. doi: 10.1042/BJ20091515.

13.

Metabolic effects of blocking lactate transport in brain cortical tissue slices using an inhibitor specific to MCT1 and MCT2.

Rae C, Nasrallah FA, Bröer S.

Neurochem Res. 2009 Oct;34(10):1783-91. doi: 10.1007/s11064-009-9973-0. Epub 2009 Apr 29.

PMID:
19404741
14.

The antineoplastic drug Paclitaxel has immunosuppressive properties that can effectively promote allograft survival in a rat heart transplant model.

Tange S, Scherer MN, Graeb C, Weiss T, Justl M, Frank E, Andrassy J, Jauch KW, Geissler EK.

Transplantation. 2002 Jan 27;73(2):216-23.

PMID:
11821733
15.

Basigin (CD147) is the target for organomercurial inhibition of monocarboxylate transporter isoforms 1 and 4: the ancillary protein for the insensitive MCT2 is EMBIGIN (gp70).

Wilson MC, Meredith D, Fox JE, Manoharan C, Davies AJ, Halestrap AP.

J Biol Chem. 2005 Jul 22;280(29):27213-21. Epub 2005 May 24.

16.

Optimization of monocarboxylate transporter 1 blockers through analysis and modulation of atropisomer interconversion properties.

Guile SD, Bantick JR, Cooper ME, Donald DK, Eyssade C, Ingall AH, Lewis RJ, Martin BP, Mohammed RT, Potter TJ, Reynolds RH, St-Gallay SA, Wright AD.

J Med Chem. 2007 Jan 25;50(2):254-63.

PMID:
17228867
17.

The low-affinity monocarboxylate transporter MCT4 is adapted to the export of lactate in highly glycolytic cells.

Dimmer KS, Friedrich B, Lang F, Deitmer JW, Bröer S.

Biochem J. 2000 Aug 15;350 Pt 1:219-27.

18.

Inhibition of host-versus-graft and graft-versus-host responses after small bowel transplantation in rats by rapamycin.

Stepkowski SM, Chen HF, Wang ME, Daloze P, Kahan BD.

Transplantation. 1992 Feb;53(2):258-64.

PMID:
1738917
19.

A ruthenium (III) polyaminocarboxylate complex, a novel nitric oxide scavenger, enhances graft survival and decreases nitrosylated heme protein in models of acute and delayed cardiac transplant rejection.

Pieper GM, Roza AM, Adams MB, Hilton G, Johnson M, Felix CC, Kampalath B, Darkes M, Wanggui Y, Cameron B, Fricker SP.

J Cardiovasc Pharmacol. 2002 Mar;39(3):441-8.

PMID:
11862124
20.

The synergism of brequinar sodium and cyclosporine used in combination to prevent cardiac allograft rejection in the rat.

Cosenza CA, Cramer DV, Eiras-Hreha G, Cajulis E, Wang HK, Makowka L.

Transplantation. 1993 Sep;56(3):667-72.

PMID:
8212165

Supplemental Content

Support Center